Loading
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Latest quote
$1.21
−$0.0261 · -2.11%
After-hours
$1.2089
−$0.0011 · -0.09%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Day range
Current $1.21
52-week range
Current $1.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
62
Bullish
Risk
85
Extreme Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Day range
Current $1.21
52-week range
Current $1.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 124.16K USD | 20.73K USD | 122.11K USD | 3.52M USD | 594.56K USD |
| Cost of goods sold | 4.8M USD | 52.6K USD | 375.85K USD | 2.11M USD | 184.18K USD |
| Gross profit | −4.68M USD | −31.87K USD | −253.73K USD | 1.41M USD | 410.38K USD |
| Research and development | 7.75M USD | 8.41M USD | 7.32M USD | 6.85M USD | 1.92M USD |
| Selling, general, and administrative | 1.56M USD | 5.4M USD | 5.64M USD | 8.54M USD | 2.36M USD |
| Operating expenses | 9.31M USD | 13.81M USD | 12.95M USD | 15.38M USD | 4.28M USD |
| Interest expense | 711.9K USD | 616.47K USD | 144.19K USD | 53.53K USD | 18.69K USD |
| Depreciation and amortization | 4.78M USD | 4.8M USD | 4.87M USD | 4.83M USD | 2.04M USD |
| Operating income | −13.99M USD | −13.84M USD | −13.21M USD | −13.98M USD | −3.87M USD |
| Net income | −14.77M USD | −14.86M USD | −13.77M USD | −14.01M USD | −3.89M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
